Use the Bayh-Dole Act to lower drug prices for government healthcare programs

Nature Medicine

Volumn 22, Issue 6, 2016, Pages 576-

  Engelberg, Alfred B ^a   Kesselheim, Aaron S ^b  

^a Engelberg Foundation   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; ENZALUTAMIDE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PRESCRIPTION DRUG;

BAYH DOLE ACT; CANCER THERAPY; COURT; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; GOVERNMENT; HEALTH CARE ACCESS; HEALTH PROGRAM; HUMAN; INVENTION; LEGAL ASPECT; LICENCE; MEDICAID; MEDICAL RESEARCH; MEDICARE; NOTE; PATENT; PRIORITY JOURNAL; PROSTATE CANCER; PUBLIC HEALTH; FINANCIAL MANAGEMENT; HEALTH CARE DELIVERY; LEGISLATION AND JURISPRUDENCE; PUBLIC POLICY; UNITED STATES;

DRUG COSTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; MEDICAID; MEDICARE; PATENTS AS TOPIC; PUBLIC POLICY; RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 84976348906     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0616-576     Document Type: Note

References (4)

1. Watanabe, T. UCLA will get hundreds of millions for rights to prostate cancer drug. LA Times (4 March 2016).
2. http://bayhdolecentral.com/JoeAllen-part3/statment.on.s.414.pdf.
3. 28 U.S.C. 1498(a) (2015).
4. Gore v. Garlock, 842 F.2d 1275, 1282 (Fed. Cir. 1988).